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Background. Asthma experienced during exercise and during the night is based on the presence of airway hyperresponsiveness
(AHR). The aim of the present study was to examine whether AHR is a predictor of exercise-induced asthma (EIA) and nighttime
symptoms. Material. We included 793 asthmatics subjects with symptoms and a positive asthma test. Results. Mean (SD) FEV1
was 93% (15), 71% had rhinitis, and 62% had atopy. Both EIA and nighttime symptoms were associated with AHR; however,
when including other factors of importance in a multivariate analysis, logRDR was eliminated, whereas FEV1% pred (P<. 001),
smoking (P<. 05), atopy (P<. 001), sex (P<. 001), and treatment (P<. 01) were associated with having EIA while dyspnoea
(P<. 001), cough (P<. 001), and eosinophils (P<. 01) were associated with frequent night symptoms. The risk of having
nighttime awakenings due to asthma was more than twofold higher among those with EIA symptoms than among those without
symptoms (OR (CI95%) 2.77 (2.0–3.8) (P<. 001)). In Conclusion. EIA and night symptoms are associated with AHR, but other
factors of importance eliminated this close association. Night asthma is more closely associated with airway inﬂammation than
AHR.
Copyright © 2009 V. Backer and L. M. Rasmussen. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
Asthma severity and asthma control are often based on the
presence and frequency of asthma symptoms, in particular
respiratory symptoms such as exercise-induced asthma,
limitation of physical activity, and frequency of night asthma
symptoms. The revised version of the GINA guidelines
from 2006 [1] recommends that disease classiﬁcation can
be changed from severity based on symptoms and airﬂow
limitations to success of disease management. Disease man-
agement is categorised as controlled, partly controlled, and
uncontrolled asthma. This is mainly based on frequency of
symptoms and continues to include limitation of physical
activity and night symptoms suggestive of level of airway
inﬂammation and increasing need of inhaled corticosteroid
(ICS).
Perception of respiratory symptoms may vary between
individuals—some might feel minor changes more than
others [2]. Physical activity is an important release of asthma
symptoms, revealing exercise-induced bronchoconstriction
[3, 4], which is widely believed to be related to either
airway inﬂammation [3]o rs m o o t hm u s c l ed y s f u n c t i o n[ 5–
8]. The primary treatment strategy in airway inﬂammation
should be inhaled steroid [9]; whereas smooth muscle
dysfunction should be treated primarily with inhaled beta-
agonist [6]. There are data to support both suggestions, but
the treatment management diﬀers. Nighttime awakenings
are probably related to increased airway inﬂammation [10,
11]; however, treatment strategies including lower dose of
ICS combined with long-acting beta2-agonist have been
found to induce a more stable disease than a higher dose of
ICS alone, which is contradictory to increased inﬂammatory
control [12]. EIA and night asthma might arise from
airway inﬂammation, but other factors, such as smooth
muscle dysfunction or diﬀerences in the patient’s percep-
tion/toleranceofsymptoms,mightplayarole.Theaimofthe
present study was to examine in a large population sample
whether AHR is of importance for the perception of EIA,
that is, positive response to a questionnaire and nighttime
symptoms. The hypothesis is that symptoms of EIA in
a general population are not usable for the diagnosis of
astma.2 Journal of Allergy
2.MaterialandMethods
2.1. Study Population. All asthmatic subjects (n = 793)
participating in two large asthma studies in our research
unit were pooled in the present analysis [13, 14]; inclusion
and exclusion criteria and the examinations performed were
the same in all studies. Subjects were aged 14–44 years (to
minimize entry of patients with COPD) and all lived in
Copenhagen, Denmark. Exclusion criteria were respiratory
illness other than asthma, for example, rhinitis as single dis-
ease,sarcoidosis,andcardiacillness.Patientswereexcludedif
they had withdrawn their consent after completing the ques-
tionnairesoriftheyhadlefttheclinicwithoutcompletingthe
clinical examination or diagnostic procedures. The studies
were approved by the local ethics committee of Copenhagen,
Denmark. All participants received information in both oral
and written form and gave their consent in writing before
enrolment.
2.2. Study Design
2.2.1. Medical History. All participants completed ﬁve self-
administered questionnaires before clinical and physical
tests. Subjects were asked about respiratory and allergic
symptoms (within the preceding four weeks and at any time
(ever asthma)), use of medication, hospital referrals, and
GP or specialist visits. The questions asked about asthma at
the interview were adapted from studies by the American
Thoracic Society, Division of Lung Disease of the National
Heart, Lung and Blood Institute [15]. Asthma was deﬁned
as asthma symptoms and signs of reversible airway disease,
that is, either airway hyperresponsiveness (AHR) to inhaled
methacholine with a PD20 ≥ 4 μmol, peak expiratory
ﬂow (PEF) variability ≥ 20%, or at least a 15% increase
in forced expiratory volume in one second (FEV1) after
administration of a bronchodilator (minimum 300mL).
2.3. Deﬁnition. Asthma severity was classiﬁed according to
the GINA guidelines (1) Mild intermittent:s y m p t o m s<once
a week, nighttime symptoms <twice a month, FEV1 > 80%
predicted. (2) Mild persistent:s y m p t o m s>once a week but
<once a day, nighttime symptoms >twice a month, FEV1
> 80% predicted. (3) Moderate persistent: daily symptoms,
nighttime symptoms > once a week or FEV1 60–80% pre-
dicted. (4) Severe: continuous daytime symptoms, frequent
nighttime symptoms or FEV1< 60% predicted. Further,
nighttime awakenings “0” (never), nighttime awakenings
(NTA) ≤ 3 per month (mild), NTA 3-4 per month (mild
persistent), NTA >4 per months and fewer than 2-3 per
week (moderate), and NTA > 4 per week (severe). The
severity of asthma (mild, mild persistent, moderate, and
severe) was classiﬁed according to the 2004 GINA guidelines,
based on symptom frequency only [16], and asthma control
was assessed according to the deﬁnition in the 2006 GINA
guidelines [1]. Details about education, socioeconomic
aspects, and lifetime consumption of tobacco in pack years
(tobacco consumption [g/day]/20 ∗ duration of smoking
[years])werecollected.Neversmokerswereparticipantswho
have never smoked, whereas smokers included daily smokers
and smokers with a more dispersed consumption. Height
and weight were measured and body mass index (BMI) was
calculated as (weight [kg])/(height [m]2).
2.4. Methods
2.4.1. Pulmonary Function Test and Methacholine Challenge
Test. Spirometry was performed on a 7-L dry wedge spirom-
eter (Vitalograph) in accordance with the ERS and the per-
centage of predicted normal values of FEV1 (FEV1%pred)
and FVC (FVC%pred), and the FEV1/FVC ratio was calcu-
lated [17]. Airway responsiveness to inhaled methacholine
was measured in accordance with the method of Yan et al.
[18] in all patients with FEV1 >70% predicted. The dose
resulting in a 20% fall in FEV1 (PD20) was calculated, and
the ratio dose response (RDR) was calculated as the decline
in FEV1 from inhaled saline divided by the highest dose
of methacholine administered [19]. A constant of four was
added to all dose-response ratios to eliminate negative and
zero values. Logarithmic transformed values of RDR were
used for analysis. Measurement of FEV1 was repeated 15
minutes after administration of 2mg terbutaline in those
with FEV1 < 70% or 15 minutes after the last inhalation of
methacholine in those with either symptoms or a signiﬁcant
decrease in FEV1 (i.e., 20%).
2.4.2. Allergy and Inﬂammatory Testing. Lastly, all subjects
underwent an allergen skin prick test with ten inhalant
allergens in accordance with the EAACI guidelines [20], and
blood eosinophils were counted (109/L).
2.5. Analysis. All data were entered in the database by one
person and 10% of all patient data were then proofread.
When this was done, quality control was conducted by
an experienced researcher on all outliers within the entire
number of variables.
Thedatawereanalyzedwiththestatisticalpack15.0SPSS
for Windows. Incidence rates were calculated for the entire
group and diﬀerences were tested by Chi-squared analysis.
Further, diﬀerences in mean (±SD) values between partici-
pants with and without respiratory symptoms were tested by
parametric analysis (Student’s t-test). All included variables
were examined in a univariate analysis with exercise-induced
asthma or nighttime awakenings due to asthma as the
dependent variable. In the event of a signiﬁcant relationship,
variables were entered in a linear regression analysis with
backward elimination of all nonsigniﬁcant parameters after
which a ﬁnal regression analysis was performed. Lastly, an
odds ratio analysis was applied in the case of dichotomy
variables. A P-value <. 05 was considered signiﬁcant.
3. Results
3.1. Basic Parameters. All 793 asthmatic subjects in the
presentsurveywereincludedbasedonrespiratorysymptoms
and a positive test to methacholine provocation, inhaled
beta-agonist or day-to-day variation in PEF (Table 1). The
frequency of rhinitis was 71% among those with certainJournal of Allergy 3
Table 1: Basic variables (mean and SD) of the entire group of
asthmatic subjects.
Variables Mean (SD)
Sex (females) 61%
Rhinitis (%) 71%
Age (years) 29. (8.3)
BMI (m2/kg) 25. (10.9)
FEV1 (L) 3.5 (0.8)
%pred FEV1 92.7 (14.9)
FVC (L) 4.33 (1.0)
%pred FVC 95.3 (13.1)
FEV1/FVC% 81.2 (8.3)
logRDR Δ%FEV1/μmol 1.02 (0.5)
Eosinophil counts (109/L) 0.24 (0.2)
Pack year (cigarettes/day) 8.21 (8.0)
asthma, 62% had positive skin prick test, and 55% were
never smokers. The frequency of exercise-induced asthma
wasasfollows:neversymptoms9%;54% ≤2timesperweek;
22% 2–6 times per week; 7% daily exercise symptoms; 8%
reportedEIAmorethanonceaday.Thenightawakeningdue
to asthma was 69%, 12%, 7%, 6%, and 6%, respectively. Of
the entire group, 29 asthmatic subjects (3.1%) reported both
severe EIA and nighttime awakenings, and 55% reported
neither symptom (P<. 001).
3.2. Univariate Analysis of EIA and Nighttime Awakenings.
A univariate analysis including severity of EIA (Table 2)
and nighttime awakenings (Table 3) showed a signiﬁcant
association between airway inﬂammation, indicated by
responsiveness to inhaled methacholine (logRDR), and
blood eosinophil count (109/L), or obstruction and severity
ofsymptoms.Theassociationbetweenairwayresponsiveness
and EIA symptoms (F = 2.5, P<. 05, and rho = 0.1, P = .01)
was less close than that between airway responsiveness and
nighttime awakenings due to asthma (F = 3.5, P<. 01 and
rho = 0.14, P<. 001). Further, no signiﬁcant association
was found between rhinitis and severe EIA (15.4% versus
15.1%, NS) and nighttime awakenings (11.9% versus 10.9%,
NS); atopic diseases was seldom seen in those with severe
EIA (10.0% versus 14.3%, P = .08) or among those with
severe night symptoms (12.4% versus 21.0%, P<. 01).
ExperienceofsevereEIAwasfrequentlyfoundamongfemale
participants (21.0% versus 7.3%, P<. 01), and nighttime
awakenings were found equally frequently among those
who had severe EIA (12.9% versus 8.5%, resp., NS). Lastly,
those with severe EIA also had many nighttime awakenings
(56.8% versus 11.4%, P<. 001); those with many nighttime
awakenings also experienced many symptoms of EIA (24.0%
versus 4.8%, P<. 001).
3.3. Multivariate Analysis of EIA and Nighttime Awakenings.
Concerning EIA, by including all variables in a multivari-
ate analysis, logRDR was eliminated; whereas FEV1%pred
(β−.16, P<. 001), smoking (β .098, P<. 05), atopy (β−.16,
P<. 001), sex (β−.18, P<. 001), and asthma treatment
(β .17, P<. 01) were found to be of signiﬁcant consequence
for development of EIA. Women reported persistent exercise
symptoms more frequently than did men (21% versus
7%, P<. 001); smokers had more EIA than nonsmokers
(18% versus 13%, P<. 05); BMI was of no importance.
Asthmatic subjects with persistent exercise symptoms had
lower lung function than those without symptoms (88%
versus 94%, P<. 001), and treatment with inhaled steroid
was more frequently used among those with persistent
exercise symptoms (41% versus 17%, P<. 001).
Including all variables in a multivariate analysis con-
cerning nighttime awakenings showed that logRDR was
eliminated as well; whereas frequency of shortness of breath
during daytime (β 0.263, P<. 001), coughing (β 0.243,
P<. 001), and EIA (β 0.102, P = .066) were of signiﬁcant
consequence. Furthermore, a higher level of eosinophils
was associated with a higher level of nighttime awakenings
(β 0.155, P<. 011). These ﬁndings showed that among
those with frequent night symptoms, 64% experienced daily
coughing, 31% had daily dyspnoea, and the eosinophil count
increasedfrom0.22109/L(nonightsymptoms)to0.35109/L
(frequent night symptoms), (normal cell count 0-0.4 109/L).
The relative risk of having nighttime awakenings due to
asthma was more than twofold higher among those with
EIA symptoms than among those without EIA symptoms.
In addition, the odds ratio (CI95%) was 2.77 (2.0–3.8) (P<
.001) of having nighttime awakenings due to asthma among
those with EIA symptoms.
4. Discussion
Although many diﬀerent surrogate variables representing
airway inﬂammation—such as bronchial responsiveness,
low level of lung function, signs of airway obstruc-
tion (low FEV1/FVC ratio), positive skin prick test, high
eosinophilic cell count, and many daily asthma symptoms—
were included in the analysis of this large uniform cohort
of persons with asthma, the study showed great diversity.
EIA and nighttime awakenings due to asthma symptoms are
symptoms of equal importance in the GINA guidelines [21]
when evaluating the severity of asthma. According to the
present guidelines, severity of asthma is based equally on the
frequency of respiratory symptoms, such as exercise-induced
asthma symptoms, and nighttime awakenings due to asthma
symptoms[21].Lesscontrolleddiseaseisusuallyanindicator
of increased airway inﬂammation, and the guidelines there-
fore suggest initiation of inhaled steroid. From a theoreti-
cal viewpoint, exercise-induced bronchoconstriction could
occuronlyintheeventofairwayinﬂammation,andthemore
severe the EIA the more severe the airway inﬂammation that
could probably be demonstrated [3–5, 11, 22]. Symptoms of
EIA in elite athletes are thus not to be used as a predictor for
asthma [23, 24] as those symptoms are not related to either
airway hyperresponsiveness to inhaled agents or to indirect
provocation. It is thus unknown whether EIA symptoms
are closely associated with airway responsiveness and airway
inﬂammation in a general population of asthmatic subjects
who have demonstrated certain airway variability, because
the majority of studies have been performed in groups
with selected asthmatic subjects who report EIA. However,4 Journal of Allergy
Table 2: Basic variables and association with EIA symptoms in an univariate analysis.
EIA 0 EIA 1 EIA 2 EIA 3 EIA 4 EIA all P-values
BMI 24 (4) 25 (4) 25 (5) 27 (7) 26 (6) 25 (5) P<. 001
Age 30 (6) 29 (8) 29 (9) 29 (8) 30 (9) 29 (8) NS
%FEV1 94 (13) 94 (14) 92 (14) 92 (14) 84 (19) 92 (15) P<. 001
%FVC 96 (10) 97 (13) 94 (13) 95 (13) 89 (14) 95 (13) P<. 001
FEV1/FVC% 81 (7) 82 (8) 81 (8) 81 (7) 79 (12) 81 (8) P<. 001
logRDR 0.95 (0.4) 0.99 (0.4) 1.06 (0.5) 1.17 (0.6) 1.03 (0.5) 1.02 (0.5) P<. 05
Eosinophils 0.23 (0.2) 0.23 (0.1) 0.25 (0.2) 0.28 (0.3) 0.20 (0.2) 0.24 (0.2) NS
Pack years 6.8 (5) 7.8 (7) 8.4 (8) 10.2 (9) 10.0 (11) 8.3 (8) NS
EIA 0 never, EIA 1 ≤ 2 per week, EIA 3 2–6 per week, EIA 3 daily, EIA 4 more than daily.
Table 3: Basic variables and association with night awakening due to asthma symptoms in a univariate analysis.
Night 0 Night 1 Night 2 Night 3 Night 4 Night all P-values
BMI 25 (5) 25 (4) 25 (5) 27 (7) 25 (5) 25 (5) P<. 01
Age 29 (8) 28 (8) 29 (8) 31 (8) 34 (7) 29 (8) P<. 001
%FEV1 94 (14) 92 (14) 88 (11) 93 (14) 82 (19) 92 (15) P<. 001
%FVC 96 (13) 96 (13) 91 (15) 97 (13) 89 (15) 95 (17) P<. 001
FEV1/FVC% 82 (8) 80 (8) 81 (8) 80 (8) 75 (12) 81 (8) P<. 001
logRDR 0.99 (0.4) 1.03 (0.4) 1.19 (0.5) 1.11 (0.6) 1.13 (0.6) 1.02 (0.5) P<. 01
Eosinophils (109/L) 0.22 (0.1) 0.25 (0.1) 0.27 (0.2) 0.30 (0.3) 0.35 (0.3) 0.24 (0.2) P<. 01
Pack years 7.7 (7) 6.9 (6) 6.0 (6) 11.3 (9) 14.8 (12) 8.2 (8) P<. 001
Night 0 never, Night ≤ 3 per month, Night 3–4 per month, Night >4 per month and fewer 2-3 per week, Night 4 > 4 per week.
the present study showed that factors important for the
presence of EIA symptoms and nighttime awakenings were
outside the battery of inﬂammatory variables.
Thesepresentﬁndingsindicateacloseunivariateassocia-
tionbetweenEIAsymptomsandAHR,whichisinagreement
with earlier ﬁndings of a close association between degree
of EIA and AHR to inhaled agents [25, 26]. However,
in the ﬁnal analysis many inﬂammatory variables were
statistically eliminated, whereas EIA symptoms continued
to show a signiﬁcant association with low level of lung
function and positive skin prick test, which could suggest
an association between markers of airway inﬂammation and
EIA in asthmatic subjects with a history of EIA symptoms.
One of which, the most important predictor of airway
inﬂammation in the present study, may be having low level
of lung function, as low level of lung function could be due
to inﬂammatory swelling of the airway mucosa [27–29].
The asthmatic women frequently reported persistent
exercise-induced symptoms; whereas nighttime awakenings
in asthmatic participants in this large population were
without sex association when interview by a specialist using
a questionnaire-based interview with focus on the issue,
as suggested by GINA guidelines [1]. We found this sex
diﬀerence interesting. It indicated that women may have a
lower tolerance to EIA or perhaps a diﬀerent perception
of EIA compared with that of men. An explanation of
women’s lower tolerance to EIA could be a symptom of
low ﬁtness, and not astma or airway inﬂammation. Women
probably perform fewer physical activities than do men,
especially among the oldest in this group; consequently,
when they exercise they develop more symptoms. Another
explanation could be the level of lung function, because
although both women and men who reported severe EIA
generally had low level lung function, the women had a
signiﬁcantly larger reduction in FEV1 percentage predicted
than did the men (data not shown), indicating that low
ventilatory capacity could also be a satisfactory explanation
of the present results of the EIA symptoms. Furthermore,
we found that more smokers than nonsmokers claimed
exercise symptoms. Other studies indicate that asthmatic
personswhoaresmokershaveimpairedeﬀectoftheirasthma
treatment, and compared with the asthmatic subjects who
were non-smokers, the asthmatic smokers showed low level
of lung function, less improvement in lung function, BHR,
and symptoms [30, 31]. These ﬁndings support our ﬁnding
of more EIA symptoms among those asthmatic subjects who
smoked, although it is unexplained whether it is due to the
smoking history or the low level of lung function, but it
seems not to be inﬂammation.
Those asthmatic subjects with severe nighttime awak-
enings seem to have more severe illness than those with
EIA symptoms. Those with night symptoms had a high
eosinophilic count; whereas the perception of exercise-
induced symptoms had a cell count which was signiﬁcantly
lower. Those with nighttime awakenings due to asthma had
a more severe degree of airway responsiveness than did those
with exercise symptoms; moreover, those who had severe
night awakening also had frequently signs of other asthma
symptoms, such as dyspnoea and cough during daytime,
all of which indicate that those with nighttime awakenings
due to asthma might have severe airway inﬂammation and
need treatment with inhaled steroid. These ﬁndings indicateJournal of Allergy 5
that symptoms of EIA may be less related to inﬂammation,
whereas nighttime awakenings are more closely related to
airway inﬂammation. The higher eosinophilic count found
among those with many night awakenings is of signiﬁcant
importance as the prognosis of asthmatic subjects with high
level of eosinophilic cell count; many respiratory symptoms
and severe AHR have been shown to be serious with a more
severe and more variable asthmatic disease [32]. Nighttime
awakenings due to asthma compared with EIA symptoms
without objective measurements are probably more likely
to be based on airway inﬂammation, which indicates that
these asthmatic subjects with nighttime awakenings, but not
symptoms of EIA, would probably beneﬁt from increased
treatment with inhaled steroid [32–34]. However, we found
a signiﬁcantly increased risk of having nighttime awakenings
among those with exercise-induced asthma symptoms. The
risk was almost threefold increased among those with many
EIA symptoms and nighttime symptoms, indicating some
association between the two diﬀerent questions of asthma
symptoms, and that although the nighttime awakenings
seem to be more closely associated with airway inﬂamma-
tion, the presence of many exercise symptoms also has some
relation to the presence of airway inﬂammation, but the
majority of symptoms might be due to low level of ﬁtness.
Based on these ﬁndings and earlier ﬁndings in elite
athletes [23, 24] the GINA guidelines would most likely
beneﬁt from reducing the importance of EIA symptoms as
an initiator of increased treatment strategy of inhaled steroid
without having an exercise test showing EIB. These ﬁndings
also emphasise the importance of objective measurement of
asthma, including objective measurement of EIA symptoms,
before including EIA as important for the level of asthma
severity and the level of control. It could be speculated,
however, whether some of these symptoms are based on a
smooth airway dysfunction rather than inﬂammation or low
level of ﬁtness, indicating need of bronchodilator and not
steroid, as all participants had proven asthma. In the present
study a substantial number of asthmatic subjects were either
untreated or undertreated [13]; this has been reported in
earlier publications. These ﬁndings of undertreatment in
the present population of asthmatic subjects highlight the
importance of the present ﬁndings. The subjects were not
contaminated with inhaled steroid, and even those who
reported serious night awakening due to asthma were not
receiving treatment according to the guidelines.
In conclusion, in this large group of asthmatic subjects
we found that EIA symptoms and night symptoms were
associated with AHR in a univariat analysis, but other factors
seem of importance for the perception of EIA and night
symptoms.SymptomsofEIAinageneralpopulationare,like
EIA symptoms in elite athletes, not usable for the diagnosis
ofastma.Nightasthmaismorecloselyassociatedwithairway
inﬂammation, which veriﬁes what we had expected.
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